Picard Medical, Inc. · AMEX:PMI
Picard Medical — Investor Presentation (August 2026)
20 slides from Picard Medical's investor presentation, August 2026
Slide 1: Investor Presentation: August 2026
NYSE: PMI Investor Presentation: August 2026 SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved.
Slide 2: Disclaimers
Disclaimers This presentation has been prepared by Picard Medical Inc. (“PMI,” the sources that the Company believes to be reliable; however, third-party “Company,” “we,” “us” or “our”) for informational purposes only and does information has not been independently verified and may be based on not p
Slide 3: Forward-Looking Statements
Forward-Looking Statements This Presentation contains statements that are “forward-looking milestones, and potential commercialization timelines. statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact These forw
Slide 4: Our Mission
To pioneer the future of heart replacement by providing the world’s Our Mission first Total Artificial Heart and developing the next-generation system as an alternative to transplantation SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned
Slide 5: SynCardia At-a-Glance
SynCardia At-a-Glance Market Leader: Global innovator in total artificial heart technology and a wholly owned subsidiary of Picard Medical, Inc. (NYSE American Ticker: PMI). Only FDA-Approved TAH: The SynCardia Total Artificial Heart (“STAH”) is the only commercially available total artificial heart
Slide 6: Driving Scalable Growth with an Experienced, Results-Focused Team
Driving Scalable Growth with an Experienced, Results-Focused Team Richard Fang, Ph.D., is the Matt Schuster was appointed Georgina Smith was appointed founder and former CEO of Chief Operating Officer in Chief Accounting Officer Reach Surgical, a minimally November 2023 after serving as effective Ju
Slide 7: Company Snapshot: Picard Medical (NYSE: PMI)
Company Snapshot: Picard Medical (NYSE: PMI) Picard Medical, Inc. Parent Company of SynCardia Systems, LLC Exchange / Ticker NYSE American: PMI Price Range $3.08 low, $684 high* Market Capitalization ~$6.75M* Average Trading Volume ~741.03K* Common Stock Issued and Outstanding 2,055,277** Options Ou
Slide 8: The Problem: Demand for Donor Hearts Continues to Exceed Supply
The Problem: Demand for Donor Hearts Continues to Exceed Supply U.S. heart transplant demand continues Significant Unmet Need: to exceed donor availability1 At least 300,0002 patients in the United States are living with advanced heart failure and may benefit from a durable 9,400+ 5,500+ 4,636 mecha
Slide 9: The Solution: The First & Only FDA Approved Total Artificial Heart (TAH)
The Solution: The First & Only FDA Approved Total Artificial Heart (TAH) Designed for Hospital and Home Use Total Artificial C2 Driver for Use Freedom Driver Heart in Hospital for Home Use The STAH is intended to replace a failing or failed human heart in patients with advanced stage heart failure a
Slide 10: Clinically Validated: Peer-Reviewed Outcomes Demonstrate STAH Survival Advantage
Clinically Validated: Peer-Reviewed Outcomes Demonstrate STAH Survival Advantage With Over 2,100 STAH Implants Survival Rate to transplantation (vs. 79% Text Text in control group)1 46% Historical pivotal clinical trial of SynCardia TAH (2004) Survival Rate at one year after heart 70% Text Text tran
Slide 11: 20 Years of Leadership: From First FDA Approval to Future Innovation
20 Years of Leadership: From First FDA Approval to Future Innovation - Proven Legacy in Total Artificial Hearts 2004 Patient Hospitalized FDA approves 70cc STAH 2012 Patient Mobile in Hospital FDA approves Companion C2 Driver 2014 Patient Mobile in Home FDA approves First and Freedom Driver 2020 Chi
Slide 12: Utilized by High Volume Transplant Centers Across the U.S. and Europe
Utilized by High Volume Transplant Centers Across the U.S. and Europe The First and Only Commercially Available Total Artificial Heart in the U.S. & Canada Center of Excellence (CoE): A high-standard transplant / heart failure center prioritized for STAH use, training, and collaboration. Selected fo
Slide 13: Lev'Veon's Story: Courage, Innovation, and a Lifesaving First
Lev’Veon’s Story: Courage, Innovation, and a Lifesaving First Age: 10 years old Mott Children’s Hospital First STAH Implant Read his story Sources: Mott Children’s Hospital, Michiganmedicine.org SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholl
Slide 14: From Patient to Patient Advocacy
From Patient to Patient Advocacy After receiving a SynCardia Total Artificial Heart, Johnny Lemucchi founded Unique Beating Hearts to help others facing advanced heart failure. Unique Beating Hearts A nonprofit providing peer support for patients and families navigating advanced heart failure. Suppo
Slide 15: Growth Drivers: Advancing Innovation, Expanding Access and Scaling Operations
Growth Drivers: Advancing Innovation, Expanding Access and Scaling Operations Innovation Pipeline Capacity & Label Expansion Advance the Emperor Drive and next-generation Increase manufacturing capacity while pursuing pneumatic driver technologies. expanded product indications and labeling. Manufact
Slide 16: Next Generation Pneumatic Driver: The Unicorn
Next Generation Pneumatic Driver: The Unicorn 2026 2028 Design freeze and Regulatory pathway bench testing 2025 2027 2029 Prototype completion Potential A lighter and quieter driver Clinical evaluation commercialization milestone for the STAH All timelines are projected and subject to change. Actual
Slide 17: Building on the STAH: Emperor TAH
Building on the STAH: Emperor TAH 2024 2026 2028 2032 Animal Implants: Emperor Drive System Potential Commercialization Independent Dual GLP Animal Studies Program initiated Milestone Motor Design1 Emperor Drive System: A compact electromechanical driver designed to replace the pneumatic FDA Breakth
Slide 18: Total Artificial Heart Technology Comparison
Total Artificial Heart Technology Comparison CARMAT SynCardia Total Artificial Heart BiVACOR® TAH Aeson® TAH Regulatory Status Approved Not approved (EFS in progress) Not approved (IDE in progress) (US) Clinical Track Most extensive: Over 2,100 implants Very early: 8 implants with ~3.5 months Limite
Slide 19: Investment Drivers: Validated, Protected and Positioned for Growth
Investment Drivers: Validated, Protected and Positioned for Growth Proven Clinical Experience The only FDA-approved Total Artificial Heart with more than 2100+ implants and decades of clinical experience. Large Unmet Market Hundreds of thousands of patients1 face end-stage biventricular heart failur
Slide 20: Thank You
SynCardia Systems, LLC / Picard Medical Inc. Addresses Most 1992 E. Silverlake Rd. Tucson, AZ 85713 | US Severe Patients +1 520-545-1234 | info@syncardia.com THANK YOU www.SynCardia.com Delivering Proven Outcomes in the SynCardia Total Artificial Heart (STAH) The STAH is approved for sale in the US